Aktis Oncology (NASDAQ:AKTS – Get Free Report) is projected to release its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to post earnings of ($0.47) per share and revenue of $4.02 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last announced its earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The firm had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $2.70 million. On average, analysts expect Aktis Oncology to post ($1.84) EPS for the current fiscal year and ($2.45) EPS for the next fiscal year.
Aktis Oncology Trading Up 3.5%
Shares of NASDAQ:AKTS opened at $16.37 on Tuesday. Aktis Oncology has a 12 month low of $13.96 and a 12 month high of $34.19. The company has a 50-day moving average price of $19.30 and a 200 day moving average price of $20.88. The company has a market cap of $879.89 million and a price-to-earnings ratio of -19.96.
Analyst Upgrades and Downgrades
AKTS has been the topic of several analyst reports. Oppenheimer began coverage on Aktis Oncology in a research note on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price objective on the stock. Wall Street Zen lowered Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Wedbush reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of Aktis Oncology in a research note on Friday, October 2nd. BMO Capital Markets began coverage on Aktis Oncology in a report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 target price for the company. Finally, Weiss Ratings downgraded Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.62.
Get Our Latest Stock Analysis on Aktis Oncology
About Aktis Oncology
Read More
- Five stocks we like better than Aktis Oncology
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
